US Edition
Study backs Biolinq sensor in GLP-1 muscle loss prevention
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Study backs Biolinq sensor in GLP-1 muscle loss prevention
The investigational intradermal glucose sensor. [Image courtesy of Biolinq]A new study has demonstrated proof of concept for a Biolinq continuous sensor in preventing muscle loss during GLP-1 therapy. Investigators presented findings as a late-breaking poster at the American Diabetes Association’s 85th Scientific Sessions in Chicago. Using a DNA-based bioreceptor (aptamer), Biolinq designed its sensor to detect phenylalanine, an essential amino …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
